Dr. Mikhail Blagosklonny’s Quest to Fight Cancer and the Effects of Aging

Rapamycin is a drug that may prove to have immense benefits for the human race. It has been used as a coating for coronary stents, for treating a rare lung disease, and as a cancer drug.

It was first isolated from a bacterium called Sirolimus found on Easter Island in 1972, and was first used as an anti-fungal agent. Mikhail Blagosklonny, a professor of Oncology at Rosewell Park Cancer Institute in Buffalo, New York, believes it can do much more. He has done monumental research on cancer and its therapies, as well as on aging. As the Editor-in-Chief of Oncotarget, a journal that publishes research papers on cancer and oncology, he has been an advocate for the use of Rapamycin for the purposes of increasing the human lifespan.

Research into the properties of Rapamycin proves its immense benefits. Here are a few of the ways it has been used:

  • Its immunosuppressant properties aid the body in accepting organ transplants. It is much less damaging to the kidneys than other anti-rejection drugs.
  • It is the primary drug used to treat Lymphangioleiomyomatosis (LAM), a rare lung disease that usually affects women of childbearing age.
  • Its use as a coronary stent coating prevents the occurrence of restenosis, or narrowing of the arteries, following balloon angioplasty.
  • Rapamycin has antiproliferative properties that help in the treatment of cancer. It can enhance the immune response and promotes tumor regression. In addition, it can reduce the risk to cancer patients when undergoing organ transplants.

While results are not conclusive yet, Dr. Mikhail Blagosklonny’s research into the anti-aging benefits of this drug is promising and certainly exciting. Tests have been done on mice and are currently being done on marmoset monkeys, as well as some initial tests on humans.

Other possible uses for Rapamycin include the treatment of Alzheimer’s, Muscular Dystrophy and Systemic Lupus Erythematosus. Research continues to show the many ways this medicine may benefit the human race, and initial results are encouraging. Dr. Mikhail Blagosklonny has been a pioneer in this research and an advocate for its use in increasing the human lifespan.

Dr. Mikhail Blagosklonny’s work as a researcher strives to find a way to eliminate cancerous cells without destroying the healthy cells in the body. He hopes to find a way to treat cancer effectively without the expense or excruciating side effects present in today’s treatments. He has made much progress in his fields of interest and hopes to inspire others in the future.

As a researcher, a professor, and a philanthropist, Dr. Mikhail Blagosklonny wants to help provide the world with the best treatment possible for cancer without regard to economic standing. He is most interested in medical research and his focus has been on both cancer and anti-aging. He continues to be influential in these fields and an inspiration to his students as well as his peers.

LinkedIn: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531/

Cancer Treatment Centers Of America Launches Platform To Optimize Cancer Care

Of the challenges with the current state of cancer treatment is that there is much more data available than any one doctor or even institution can keep track of by itself. Collating and assembling the wisdom of the medical crowd into a best practices for cancer treatment is the holy grail of oncology.

To that end, the Cancer Treatment Centers of America have partnered with AllScripts and NantHealth to launch Clinical Pathways, a comprehensive collection of the latest cancer care data. Using the platform, physicians and other healthcare professionals can access a wealth of treatment data from hospitals and other medical institutions across the United States. Clinical Pathways allows doctors to see the treatments with the best results and optimize outcomes and costs across a wide range of variables. This data helps patients, doctors and other interested parties examine the data and make the best possible decision.

Cancer Treatment Centers of America is a national network of five for-profit hospitals that specialize in cancer treatment. The first Cancer Treatment Centers of America hospital was founded in 1988 after Richard J Stephenson’s mother died as the result of her cancer. He was unhappy with the treatment she received and became convinced there was a better way to tackle this terrible disease.

The company is now based in Boca Raton, Florida and has institutions in Illinois, Georgia, Arizona, Pennsylvania and Oklahoma. The Cancer Treatment Centers of America also has offices in a number of countries in Europe and the Middle East, which can diagnose and funnel patients to the five American hospitals for treatment.

Eric Lefkofsky Leads the Charge Fighting Cancer with Tempus Company

Eric Lefkofsky is has helped lead to the rise of the Tempus businesses and their data-enabling precision technology that allows precision medicine to help patients who are suffering from cancer or other similar conditions. Lefkofksky precision medicine is in growing demand as more than 40% of US adults facing some type of cancer diagnosis at some point and everyone knows someone who has fought a battle with cancer in their lifetime. The cancer institute says there were about 14.5 million people living with cancer in 2014. The figure is expected to rise to about 19 million by 2024, however, thanks to improvements in treatments prognosis for people with cancer is looking better than ever before as people like Lefkofsky pioneer medicine to help people win their battles with cancer.

Eric Lefkofsky is the co-founder and CEO of the Tempus company which uses the latest technology to build operating systems that help people fighting cancer. He is also the founder of Lightbank which is venture fund that invests money in disruptive technologies. Lefkofsky also invests in several other companies that help contribute technology to his Tempus company and help fight against the cancers that they are trying to cancet treatment and find cures for.

On the side, Eric Lefkofsky is a philanthropist and in 2006 he established his very on Lefkofsky Family Foundation which he started with his wife Liz to help advance high-impact initiatives in lower-income communities to help enhance the lives of the people living in those communities. In his spare time, Lefkofsky also serves as a Chairman of the Board of Trustees of the Steppenwolf Theatre Company and also does extensive work with the Chicago are children’s hospitals as well to learn more: http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life click here.

He also serves as an adjunct professor at the University of Chicago and is the author of his own book the “Accelerated Disruption” where he talks about his work he does to fight cancer and how to disrupt the pattern of it growing in the human body with the technology we have today.